Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma

被引:69
作者
Li, SJ
Liu, GY
Jia, JY
Li, XC
Yu, C [1 ]
机构
[1] Shanghai Xuhui Cent Hosp, Cent Lab, Shanghai 200031, Peoples R China
[2] Chinese Acad Sci, Dept Pharmacol, Shanghai Inst Mat Med, Shanghai Inst Biol Sci, Shanghai 201203, Peoples R China
关键词
ezetimibe; LC-MS/MS; negative electrospray ionization;
D O I
10.1016/j.jpba.2005.07.053
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple, reliable and sensitive liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was developed and validated for quantification of free and total ezetimibe in human plasma. The analyte and internal standard ((13)C6-ezetimibe) were extracted by liquid-liquid extraction with methyl tert-butyl ether. The reversed-phase chromatographic separation was performed on a Capcell C18 column, and the plasma extract was eluted with a gradient consisting of acetonitrile and 5 mM ammonium acetate. The analyte was detected using negative ionization by multiple reaction monitoring mode. The mass transition pairs of m/z 408.5 -> 270.8 and m/z 414.5 -> 276.8 were used to detect ezetimibe and internal standard, respectively. The assay exhibited linear ranges from 0.02 to 20 ng/ml for free ezetimibe and 0.25 to 250 ng/ml for total czetimibe in human plasma. Acceptable precision and accuracy were obtained for concentrations of the calibration standard and quality control. The validated method was successfully used to analyze human plasma samples for application in a pharmacokinetic study. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:987 / 992
页数:6
相关论文
共 12 条
[1]   Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia [J].
Ballantyne, CM ;
Blazing, MA ;
King, TR ;
Brady, WE ;
Palmisano, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) :1487-1494
[2]   A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].
Bays, HE ;
Ose, L ;
Fraser, N ;
Tribble, DL ;
Quinto, K ;
Reyes, R ;
Johnson-Levonas, AO ;
Sapre, A ;
Donahue, SR .
CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773
[3]   Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies [J].
Bays, HE ;
Moore, PB ;
Drehobl, MA ;
Rosenblatt, S ;
Toth, PD ;
Dujovne, CA ;
Knopp, RH ;
Lipka, LJ ;
LeBeaut, AP ;
Yang, B ;
Mellars, LE ;
Cuffie-Jackson, C ;
Veltri, EP .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1209-1230
[4]   Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia [J].
Dujovne, CA ;
Ettinger, MP ;
McNeer, JF ;
Lipka, LJ ;
LeBeaut, AP ;
Suresh, R ;
Yang, B ;
Veltri, EP .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (10) :1092-1097
[5]   Effectiveness of ezetimibe in clinical practice [J].
Jurado, J ;
Seip, R ;
Thompson, PD .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (05) :641-643
[6]   Efficacy and safety of Ezetimibe coadministered with Lovastatin in primary hypercholesterolemia [J].
Kerzner, B ;
Corbelli, J ;
Sharp, S ;
Lipka, LJ ;
Melani, L ;
LeBeaut, A ;
Suresh, R ;
Mukhopadhyay, P ;
Veltri, EP .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (04) :418-424
[7]  
Knopp RH, 2003, INT J CLIN PRACT, V57, P363
[8]   Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment:: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study [J].
Masana, L ;
Mata, P ;
Gagné, C ;
Sirah, W ;
Cho, M ;
Johnson-Levonas, AO ;
Meehan, A ;
Troxell, JK ;
Gumbiner, B .
CLINICAL THERAPEUTICS, 2005, 27 (02) :174-184
[9]   Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):: A designed, potent, orally active inhibitor of cholesterol absorption [J].
Rosenblum, SB ;
Huynh, T ;
Afonso, A ;
Davis, HR ;
Yumibe, N ;
Clader, JW ;
Burnett, DA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (06) :973-980
[10]  
Simard Chantale, 2003, Can J Clin Pharmacol, V10 Suppl A, p13A